SEOUL, South Korea--(BUSINESS WIRE)--Icure Pharmaceutical Inc. (KOSDAQ: 175250), a biopharmaceutical company in Korea, announced today that its donepezil patch, a treatment of Alzheimer’s-type dementia, received a drug product approval from the Ministry of Food and Drug Safety of Korea.
Celltrion announced on Nov. 5 that it will start phase 3 clinical trials of its patch-type donepezil, a medication that aims to treat people with Alzheimer’s disease, jointly with local drugmaker Icure.